Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 4:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Tumour Response. Clear all
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting No phase listed Observational

The Immune System's Response to Young Women's Breast Cancer

NCT01503190
View directory record Official record
Conditions
Breast Cancer, Breast Cancer and Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions
Single Agent Asciminib, Low TKI, Elective Free Treatment
Drug · Combination Product · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional

A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma

NCT00001113
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents

NCT02055586
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorine F 18 fluorothymidine, positron emission tomography, magnetic resonance imaging
Other · Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Not yet recruiting Phase 2 Interventional

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

NCT07803562
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Active, not recruiting Phase 2 Interventional

Intrapleural Catheter Daily Versus Three Times a Week Drainage

NCT00761618
View directory record Official record
Conditions
Advanced Cancer, Pleural Effusion
Interventions
Intrapleural catheter (IPC) drained, IPC Placement, Chest X-Ray
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Not applicable Interventional

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

NCT00953446
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Completed No phase listed Observational

Advanced MR Imaging in Sarcoma Patients

NCT02705391
View directory record Official record
Conditions
Sarcoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Early Phase 1 Interventional

Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic Cancer

NCT07254091
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Device Arm with Therapeutic Agents
Combination Product
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Early Phase 1 Interventional

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

NCT00757549
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy
Biological · Drug · Genetic + 2 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Not applicable Interventional

Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response

NCT04588025
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Point-of-care Portable Perfusion Phantom, P4
Device
Lead sponsor
Ohio State University
Other
Eligibility
19 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus QS21 in Treating Patients With Small Cell Lung Cancer That Has Responded to Initial Therapy

NCT00004249
View directory record Official record
Conditions
Lung Cancer
Interventions
QS21, keyhole limpet hemocyanin, polysialic acid
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn Phase 3 Interventional

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

NCT02392676
View directory record Official record
Conditions
Platinum Sensitive Relapsed Ovarian Cancer
Interventions
OLAPARIB, PLACEBO
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 96 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
15
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Sep 17, 2026, 4:08 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging

NCT04273555
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
[18F]-FDG
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 1 Interventional Results available

Cancer Vaccine Targeting Brachyury Protein in Tumors

NCT01519817
View directory record Official record
Conditions
Neoplasms, Malignant Solid Tumors, Colon Neoplasms, Adenocarcinoma
Interventions
GI-6301 (Yeast Brachyury Vaccine)
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 2 Interventional Results available

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

NCT01133678
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Everolimus, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 17, 2026, 4:08 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma

NCT00775268
View directory record Official record
Conditions
Lymphoma
Interventions
Biopsy, fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography, [3'-deoxy-3'-[F-18] fluorothymidine, computed tomography, fine-needle aspiration
Procedure · Diagnostic Test · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab tirumotecan, Capecitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
92
States / cities
Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 77 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 17, 2026, 4:08 AM EDT
Suspended No phase listed Observational

Predicting Response of Metastatic Triple Negative Breast Cancer to Immunotherapy Based on Patients Cytokine Profile

NCT04250818
View directory record Official record
Conditions
Metastatic Triple-Negative Breast Cancer
Interventions
Not listed
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

NCT00468546
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MabThera/Rituxan, Methotrexate, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
67
States / cities
Birmingham, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Sep 17, 2026, 4:08 AM EDT
Completed Not applicable Interventional

Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study

NCT00907140
View directory record Official record
Conditions
Cervical Cancer
Interventions
Positron Emission Tomography
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 17, 2026, 4:08 AM EDT